Panacea Biotec Limited has informed the Exchange about change in directors in the Company's material wholly owned subsidiary, Panacea Biotec Pharma Limited
PANACEABIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Panacea Biotec's material wholly owned subsidiary, Panacea Biotec Pharma Limited (PBPL), has announced board changes. The board has approved appointment of Mr. Krishan Kumar Jalan as an additional non-executive independent director from July 1, 2026, until February 13, 2030. Additionally, Mrs. Manjula Upadhyay has been re-appointed as a non-executive independent director for another 5-year term from July 23, 2026, to July 22, 2031. Mr. Jalan is a retired IAS officer with 35 years of experience in Indian administration and currently serves as independent director on multiple listed companies. Mrs. Upadhyay is a practicing lawyer with 37 years of experience in labour laws. Both appointments are subject to shareholder approval.
These are routine governance updates in a subsidiary and do not signal any concern. The appointment of experienced independent directors may strengthen board oversight at PBPL. No direct impact expected on Panacea Biotec's stock price.